Genmab A/S (NASDAQ:GMAB) Given “Underweight” Rating at Morgan Stanley

Genmab A/S (NASDAQ:GMABGet Free Report)‘s stock had its “underweight” rating restated by stock analysts at Morgan Stanley in a research note issued on Tuesday, Benzinga reports.

A number of other analysts also recently issued reports on GMAB. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, March 6th. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. UBS Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Truist Financial reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Tuesday. Finally, BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $46.00 to $48.00 in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Hold” and an average price target of $48.50.

Get Our Latest Analysis on GMAB

Genmab A/S Stock Down 1.6 %

NASDAQ:GMAB traded down $0.49 during midday trading on Tuesday, hitting $30.14. The stock had a trading volume of 24,660 shares, compared to its average volume of 636,743. The stock has a 50-day moving average of $28.85 and a 200 day moving average of $31.10. The company has a market capitalization of $19.91 billion, a price-to-earnings ratio of 31.91, a PEG ratio of 1.44 and a beta of 0.98. Genmab A/S has a one year low of $26.32 and a one year high of $42.99.

Genmab A/S (NASDAQ:GMABGet Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.34 by $0.02. The firm had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, sell-side analysts anticipate that Genmab A/S will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Alliancebernstein L.P. lifted its position in Genmab A/S by 21.0% in the 2nd quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock valued at $311,210,000 after purchasing an additional 1,420,915 shares during the last quarter. Millennium Management LLC raised its position in Genmab A/S by 655.9% during the fourth quarter. Millennium Management LLC now owns 919,408 shares of the company’s stock valued at $38,965,000 after buying an additional 797,770 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Genmab A/S by 93.6% in the third quarter. Envestnet Asset Management Inc. now owns 946,880 shares of the company’s stock worth $33,396,000 after acquiring an additional 457,772 shares during the last quarter. Morgan Stanley lifted its stake in Genmab A/S by 40.1% in the fourth quarter. Morgan Stanley now owns 1,215,861 shares of the company’s stock valued at $51,528,000 after acquiring an additional 347,824 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of Genmab A/S by 11.1% in the first quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock worth $131,580,000 after buying an additional 347,437 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Recommended Stories

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.